Search Results

You are looking at 31 - 40 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)

and Oncology . Int J Radiat Oncol Biol Phys 1998 ; 41 : 267 – 272 . 26. Thompson A Keyes M Pickles T . Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kinetics distinguish PSA

Full access

Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, and Anthony V. D'Amico

following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database . BJU Int 2010 ; 105 : 28 – 33 . 31. Lee AK D'Amico AV . Utility of prostate-specific antigen kinetics in

Full access

Matthew Zibelman and Anthony J. Olszanski

melanoma . Expert Rev Anticancer Ther 2009 ; 9 : 587 – 595 . 18. Weber JS Kähler KC Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab . J Clin Oncol 2012 ; 30 : 2691 – 2697 . 19

Full access

Michael Angarone and Michael G. Ison

-load kinetics to identify patients who develop cytomegalovirus disease after transplantation . Lancet 2000 ; 355 : 2032 – 2036 . 51. Ljungman P Aschan J Lewensohn-Fuchs I . Results of different strategies for reducing cytomegalovirus

Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, and Pamela S. Becker

://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf 14. de Araujo OR , Salomão R , Brunialti MKC , . Cytokine kinetics in febrile neutropenic children: insights on the usefulness as sepsis biomarkers, influence of filgrastim, and behavior of the IL-23/IL-17 pathway

Full access

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, and Steven Brem

multiforme . J Clin Oncol 1999 ; 17 : 2572 – 2578 . 2. Winkler F Kozin SV Tong RT . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy . J Clin Oncol 2009 ; 27 : 3518 – 3525 . 95 Lonial S Waller EK Richardson PG . Risk factors and kinetics of

Full access

Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss

. Adelsberger H , Quasthoff S , Grosskreutz J , . The chemotherapeutic oxaliplatin alters voltage-gated Na + channel kinetics on rat sensory neurons . Eur J Pharmacol 2000 ; 406 : 25 – 32 . 10.1016/S0014-2999(00)00667-1 11011028 4. Descoeur J

Full access

Jorge Cortes, John M. Goldman, and Timothy Hughes

, underscoring the different response kinetics between the agents), and values of 0.92% and 0.57% were predictive of 3-log and 4.5-log reductions, respectively. The results of these studies support the use of earlier molecular testing to assess response in

Full access

Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr

patients with BRAF -mutated tumors was approximately 1 year. 21 , 22 The explanation for the poor survival of patients with BRAF -mutated mCRC is incompletely understood but may relate to inherent chemoresistance, aggressive disease biology and kinetics